or
Bookmark and Share
Antibiotic substance
   
Document Number
US Patent 3890435
Issued Date
June 17, 1975
Link
Map
Abstract
The new compound known as cytochalasin E and a process for its manufacture by cultivation of the organism Rosellinia Necatrix. The compound produces effects on tissue culture cells and is useful in the study of cytological processes.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
2
Comments:
no comments yet
Published
June 17, 1975
Application Number
05/132,181
Filed
April 7, 1971
US Classification
424/115   435/119 435/911
Int'l Classification
A61K   38/43   (20060101)   A61K   38/46   (20060101)  
Attorney/Law Firm
USPTO Field of Search
424/115   195/81  
Related Patents
5876676 - Preservation of blood platelets - Owned by Brigham and Women's Hospital, Inc. (Boston, MA)

Methods and compositions for preserving platelets at cryogenic temperatures with retention of hemostatic activity are provided. The compositions include a first agent for inhibiting actin filament severing and a second agent for inhibiting actin polymerization. Contacting the platelets with the first and second agents prior to exposure to cold temperature prevents cold-induced platelet activation.

5576213 - Preservation of blood platelets - Owned by Brigham & Women's Hospital, Inc. (Boston, MA)

Methods and compositions for preserving platelets at cryogenic temperatures with retention of hemostatic activity are provided. The compositions include a first agent for inhibiting actin filament severing and a second agent for inhibiting actin polymerization. Contacting the platelets with the first and second agents prior to exposure to cold temperature prevents cold-induced platelet activation.

5358844 - Preservation of blood platelets - Owned by Brigham and Women's Hospital, Inc. (Boston, MA)

Methods for preserving platelets at temperatures of less than about 15.degree.C. with retention of hemostatic activity are provided. The method uses a first agent for inhibiting actin filament severing and a second agent for inhibiting actin polymerization. Contacting the platelets with the first and second agents prior to exposure to cold temperature prevents cold-induced platelet activation.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us